5-Fluorouracil/folinate/oxaliplatin (Eloxatin) (FLOX [FOLFOX] regimen), given continuously or intermittently, in combination with cetuximab (Erbitux), in first-line treatment of metastatic colorectal cancer. A phase III multicenter trial.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms Nordic-VII
- 21 Sep 2020 Results of meta analysis validating the efficacy and safety between Q2W vs. Q1W CET dosing presented at the 45th European Society for Medical Oncology Congress
- 01 Aug 2017 Results evaluating the effect of cetuximab on health-related quality of life (HRQoL) in the NORDIC-VII trial on metastatic colorectal cancer (mCRC), published in the European Journal of Cancer.
- 11 Apr 2017 Results of final survival analyses and extended RAS data published in the British Journal of Cancer.